Astellas Pharma Inc

Introduction
Astellas Pharma Inc. is a leading Japanese multinational pharmaceutical company formed in 2005 through the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd. Astellas focuses on oncology, urology, immunology, neuroscience, and rare diseases, with a strong emphasis on innovative therapies and advanced technologies. The company is recognized for its patient-centric approach and commitment to addressing unmet medical needs worldwide.

Mission and Vision

Mission: To contribute toward improving the health of people around the world through the provision of innovative and reliable pharmaceutical products.
Vision: To be on the forefront of healthcare innovation, creating value by turning innovative science into value for patients.

Products and Services

Oncology: Xtandi (for prostate cancer), Padcev, and other cancer therapies.
Urology: Treatments for overactive bladder and related conditions.
Immunology & Transplantation: Prograf (tacrolimus), widely used in organ transplantation.
Neuroscience: Pipeline research in neurological and psychiatric conditions.
Gene & Cell Therapy: Expanding portfolio in advanced therapeutics.
Rare Diseases: Focus on unmet needs in genetic and metabolic disorders.

Growth and Innovation
Astellas has strategically invested in oncology and advanced therapies, making it one of the fastest-growing pharma companies in Japan and globally. With its acquisition of Audentes Therapeutics, Astellas has expanded into gene therapy. The company is also actively developing cell therapies, regenerative medicine, and digital health solutions to shape the future of healthcare.

Global Impact
Operating in more than 70 countries, Astellas provides medicines that reach millions of patients globally. Its cancer therapies and transplant medicines have had a significant impact on global healthcare. The company is also committed to sustainability, aiming for carbon neutrality and expanding patient access programs to underserved regions.